title: VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
authors.forename: Selmin
authors.initials: S
authors.lastname: Ataergin
authors.forename: Fikret
authors.initials: F
authors.lastname: Arpaci
authors.forename: Ayper
authors.initials: A
authors.lastname: Kaya
authors.forename: Turker
authors.initials: T
authors.lastname: Cetin
authors.forename: Turker
authors.initials: T
authors.lastname: Kaya
authors.forename: Omer
authors.initials: O
authors.lastname: Gunhan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011480:Protease Inhibitors / Q000008:administration & dosage*; D011719:Pyrazines / Q000008:administration & dosage*; D012074:Remission Induction
chemical_list: D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D005047:Etoposide; D004317:Doxorubicin